Pharmacokinetics of FCE 22891, a new oral penem.

AUTOR(ES)

Saathoff, A

RESUMO

FCE 22891 is the oral prodrug of FCE 22101, a new broad-spectrum penem. The pharmacokinetics of FCE 22891 after single-dose administration, its absolute bioavailability, and the effect of food intake on its absorption were investigated in three different randomized crossover studies in healthy volunteers. Drug levels in blood and urine were measured by high-pressure liquid chromatography and bioassay. For optimal comparison of the results of all studies, and since there was good agreement of both methods, only the high-pressure liquid chromatography results are included. The pharmacokinetics of the penem were linear, and its bioavailability after oral administration was 42 +/- 11%. Food intake increased the total area under the curve from 0 h to infinity from 11.9 +/- 3.5 to 14.1 +/- 2.4 mg.h/liter. A specific side effect, i.e., bladder complaints, was registered in some volunteers taking FCE 22891 at doses greater than or equal to 1.0 g.

Documentos Relacionados

• Pharmacokinetics of [14C]FCE 22891, a penem antibiotic, following oral administration to healthy volunteers.
• Antibacterial activity of HRE 664, a new parenteral penem.
• In vitro activity of CGP 31608, a new penem.
• Comparison of in vitro activity of FCE 22101, a new penem, with those of other beta-lactam antibiotics.
• Clinical and bacteriological efficacy and tolerability of FCE 22891 in patients with exacerbations of chronic obstructive pulmonary disease.